BLCM Bellicum Pharmaceuticals Inc
Bellicum Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The firm is primarily engaged in the research of cellular immunotherapies for hematological cancers, solid tumors, and orphan inherited blood diseases.
$1.44
As of 05/25/2022 IEX book CBOE book
Security Information
Category1:
US EquityCategory2:
Common stocksCategory3:
Micro cap
GICS sector: Health Care
Industry: Biotechnology
Index country: USA
Country of incorporation: USA
IPO date: 12/18/2014
Outstanding shares: 8,609,661
Average volume: 23,525
Market cap: $11,623,042
Current dividend yield: 0.00%
All SEC filings:
SEC Edgar Online
Quarterly filings:
10-Q
Annual filings:
10-K
Sedol:
Valuation (See tab for details)
PE ratio: 11.42
PB ratio: 0.72
PS ratio: 0.00
Return on equity: 21.20%
Net income %: 0.00%